Cipla drops after weak Q2 results

Cipla lost 0.91% to Rs 408.80 at 11:07 IST on BSE after consolidated net profit declined 26.6% to Rs 358 crore on 14% growth in revenue to Rs 2463 crore in Q2 September 2013 over Q2 September 2012.

The Q2 result was announced after market hours on Wednesday, 13 November 2013.

Meanwhile, the S&P BSE Sensex was up 366.02 points or 1.81% at 20,560.42.

On BSE, 68,000 shares were traded in the counter as against average daily volume of 1.01 lakh shares in the past two weeks.

The stock hit a high of Rs 411.90 and a low of Rs 405.25 so far during the day.

Cipla Medpro South Africa (Medpro), a pharmaceutical company, incorporated in South Africa became a wholly owned subsidiary of Cipla on 15 July 2013. Accordingly, the Q2 September 2013 result includes the relevant results of Medpro and its subsidiaries from the date Medpro became subsidiary of the company and therefore the corresponding figures for the previous period are not comparable, Cipla said.

The Q2 September 2012 revenue includes one-time profit share revenues from Escitalopram through the company's US partner. EBITDA (earnings before interest, taxation, depreciation and amortization) declined 19.6% to Rs 564 crore in Q2 September 2013 over Q2 September 2012.

Cipla's domestic revenue rose 11.6% to Rs 1040 crore in Q2 September 2013 over Q2 September 2012. The growth in domestic revenues was largely on account of growth in anti-asthma, urology and COPD therapy segments, Cipla said in a statement.

Cipla's revenue from exports of formulations grew 14.9% to Rs 1219 crore in Q2 September 2013 over Q2 September 2012. Exports of APIs grew 17.7% to Rs 204 crore in Q2 September 2013 over Q2 September 2012. The growth in export revenue was primarily due to growth in anti-retroviral, anti-malaria and anti-allergic segments, Cipla said in a statement.

Cipla is a pharmaceutical company. With over 34 manufacturing units across the country, Cipla manufactures over 2000 products in 65 therapies. With a turnover of over $1.5 billion, Cipla serves doctors and patients in over 170 countries.

Powered by Capital Market - Live News